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ABSTRACT
Placebo treatments have long been used to study the psychological effects of expectancy and
conditioning on an inert intervention. Interestingly, open-label placebo treatments (i.e., directly
telling subjects they are receiving an inactive intervention) have recently shown promise in
minimizing pain in clinical patient populations. We utilized a repeated measures design to
examine the acute effects of placebo, open-label placebo, and control treatments on muscle
strength and voluntary activation (Experiment #1), as well as neuromuscular fatigue (Experiment
#2). Twenty-one untrained males (n=11) and females (n=10) visited the laboratory on three
occasions to receive each treatment in a randomized, counter-balanced manner. All visits
involved a pretest, 15-minute intervention period, and posttest. In Experiment #1, knee extensor
maximal voluntary isometric contraction (MVIC) peak torque and percent voluntary activation
were evaluated. In Experiment #2, subjects performed 20, six-second MVICs while surface
electromyographic signals were detected from the vastus lateralis. Subjective assessments of
energy and perceived exertion were also examined. In Experiment #1, no differences among
interventions were demonstrated for peak torque or voluntary activation, but a main effect
revealed that energy levels increased following each treatment (p = .016, η2 = .257). Experiment
#2 demonstrated that placebo and open-label placebo treatments had no influence on
neuromuscular fatigue, but there were main effects for declines in absolute (p = .001, η2 = .675)
and normalized peak torque (p = .001, η2 = .765), electromyographic mean frequency (p = .001,
η2 = .565), neuromuscular efficiency (p = .001, η2 = .585), and energy levels (p = .006, η2 =
.317). Collectively, placebo and open-label placebo treatments had minimal influence on
strength, voluntary activation, and fatigue resistance in untrained subjects. We speculate that our
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subject population and study design intricacies that are unique to placebo trials may explain our
findings.
Keywords: Open-label placebo, maximal voluntary isometric contraction, neuromuscular fatigue
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CHAPTER ONE: INTRODUCTION
Placebo treatment is the use or administration of an inert substance or treatment with the
expectation that the substance has active ingredients or the treatment has been known to work
(Carvalho et al., 2016; Kaptchuk et al., 2010; Tilburt, Emanuel, Curlin, & Miller, 2008). Placebo
analgesia is the phenomenon of the placebo effect that is used to reduce pain mostly by
psychological effects, but may also have the ability to release endorphins in the brain (Kirsch et
al., 2014; Medoff, & Colloca, 2015). The overall consensus of research attributes the
psychological effects to brain mechanisms which are learning phenomenon, such as expectancy
and conditioning. Expectation for placebo treatments can derive from social observation, sources
of information, or verbal information. Conditioning is the direct experience of previous treatment
with an actual outcome (Kalasountas, V., Reed, J., & Fitzpatrick, J., 2007; Kirsch et al., 2014).
The effectiveness of placebo treatments is based off of expectancy and conditioning to produce a
positive psychological response (Kirsch et al., 2014; Tilburt, Emanuel, Curlin, & Miller, 2008).
Placebos have been used in research science, clinical medicine, and a variety of
disciplines in attempts to produce an altered outcome to existing treatments. Placebo treatments
can be found being used by physicians on a regular basis with patients without their knowledge
(Tilburt, Emanuel, Kaptchuk, Curlin, & Miller, 2008). Outside of clinical research, the use of
placebos can be seen with sports and athletic performance. Placebo treatment studies have shown
improvements in one-repetition maximum strength in bench press and seated leg press with
novice lifters (Kalasountas, V., Reed, J., & Fitzpatrick, J., 2007) and in power lifters
performance by significantly improving strength enough to move them from the national to
international level (Maganaris, C.N., Collins, D., & Sharp, M., 2000).
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Placebo treatments have traditionally been blinded processes, but recently the use of
open-label placebo treatments has shown interesting results. Open-label placebo (OLP) treatment
is a non-deceptive type treatment where subjects are directly told they are receiving inactive
ingredient filled capsules. The use of OLP treatments have been used on patients with cancerrelated fatigue (Hoenemeyer, Kaptchuk, Mehta, & Fontaine, 2018), chronic lower back pain
(Carvalho et al., 2016), Irritable Bowel Syndrome (Kaptchuk et al., 2010), attention deficit
hyperactivity disorder (Sandler, & Bodfish, 2008), episodic acute migraine attacks (Kam-Hansen
et al., 2014), allergic rhinitis (Schaefer, Sahin, & Berstecher, 2018), and major depressive
disorder (Kelley, Kaptchuk, Cusin, Lipkin, & Fava, 2012;). With majority of these studies, the
OLP treatments have shown improvements in symptoms. Open-label placebo studies have shown
reduction in cancer-related fatigue (Hoenemeyer, Kaptchuk, Mehta, & Fontaine, 2018),
reduction in chronic lower back pain (Carvalho et al., 2016), and improvements in relief and
reduction in symptom severity with Irritable Bowel Syndrome (Kaptchuk et al., 2010).
Placebo and OLP treatments have covered a vast range of illnesses, disorders, and
diseases, but few have examined the ability to delay neuromuscular fatigue during maximal
contractions. The positive outcomes of the recent OLP clinical trials suggest that deception may
not be necessary for placebos to be beneficial. Placebo treatments are considered an unethical
practice due to the violation of a person’s autonomy and informed consent (Tilburt, Emanuel,
Curlin, & Miller, 2008). With the use of an OLP, the subjects are able to keep both of these
throughout the duration of the treatment or study. The purpose of this study was to compare the
effects of placebo versus open-label placebo supplementation on muscle strength, voluntary
activation, and muscle fatigue during repeated maximal strength testing. We hypothesized that
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both placebo and open-label placebo supplementation will result in less reduction in muscle
fatigue, voluntary activation, and neuromuscular fatigue compared with a control condition.

3

CHAPTER TWO: METHODOLOGY
Study Design
This study utilized a repeated measures design to compare placebo supplementation,
open-label placebo supplementation, and a control condition on muscle strength and fatigue
resistance in young adults. An overview of the design has been provided in Figure 1. For ease of
comprehension, muscle strength and fatigue resistance analyses have been described as
Experiments #1 and #2, respectively. The subjects in this study visited the laboratory on four
separate occasions, with the first serving as a familiarization session. All visits were at the same
time of day (± one hour). The time between trial days was ≥ 48 hours but < one week.
Conditions in the laboratory were kept constant, including the personnel involved in data
collection and analysis. The subjects were asked to keep their physical activity levels, sleep,
dietary habits, and caffeine consumption consistent throughout the study. With the exception of
the intervention (placebo, open-label placebo, and control) provided during the three trials, all
aspects of data collection were identical. All testing involved maximal voluntary and involuntary
contractions of the dominant knee extensors.

Subjects
Twenty-one untrained subjects (eleven males: mean ± SD age = 22.7 ± 3.2 years, mass =
72.03 ± 13.1 kg, height = 1.7 ± 0.06 m; ten females: age = 21.7 ± 3.02 years, mass = 62.2 ± 12.3
kg, height = 1.7 ± 0.07 m) participated in this study. Individuals were recruited via flyers posted
throughout the University of Central Florida campus, social media advertisements, word-ofmouth, and announcements made in classes (Appendix B). For inclusion criteria, healthy males
and females had to be between 18 and 35 years of age. Subjects had to have a body mass index
4

of ≤ 30 kg/m2, refrained from moderate-intensity lower-body exercise (average ≤ three times per
month) within the previous six months, and refrained from dietary supplement consumption
within the past year. Exclusion criteria included a history of myocardial infarction, metabolic or
neuromuscular disease, hip or knee joint surgery, osteoarthritis of the knee or hip,
musculoskeletal pain, or allergies to rubbing alcohol. In addition, individuals with flour, gluten,
or wheat allergies were excluded, as were those that were unable to swallow pills. Prior to
enrollment, potential subjects completed pre-testing health questionnaire (Appendix D) and
Physical Activity Readiness Questionnaire (Appendix E) forms. All subjects were made aware of
the study procedures prior to enrollment and signed informed consent documents. The University
of Central Florida’s Institutional Review Board approved of this study (ID # SBE-17-13539).

Assessment of Isometric Torque
Isometric torque testing of the dominant knee extensors (based on kicking preference)
was performed with a Biodex System 4 isokinetic dynamometer (Biodex Medical Systems,
Shirley, NY, USA). The chair was adjusted such that the subject’s axis around the knee was
parallel with the axis of rotation of the dynamometer. The seat was adjusted to acquire a 110°of
flexion at the hip and a 70°of flexion at the knee (0°= full extension). Restraining straps were
tightly fastened around the subject’s hips, waist, chest, and non-dominant leg to limit extraneous
movement of the limbs and torso. The tibia of the dominant leg was secured to an Anti-Shear
attachment (Biodex Medical Systems, Shirley, NY, USA), which was positioned over the tibialis
anterior muscle just superior to the malleoli. Each subject’s dynamometer settings were recorded
during the initial visit to the laboratory to ensure consistency from trial-to-trial. The subjects
grasped the stabilization handles throughout testing. All testing was proceeded by a submaximal
5

warm-up which consisted of three, 10 second isometric contractions at 50% of the subject’s
perceived maximum torque level followed by 10 seconds of rest (i.e., 10 seconds “on,” 10
seconds “off”).

Interpolated Twitch Technique
Electrical stimulation of the quadriceps femoris muscles was used to quantify percent
voluntary activation. (Button & Behm, 2008) The methodology used in the present study was
similar to that described by Park et al. (2008) Two 7.5 cm x 10 cm PALS Neurostimulation
adhesive surface electrodes (Axelgaard Manufacturing Co., LTD, Fallbrook, CA, USA) were
placed on the quadriceps muscles, with one over the vastus medialis and one over the vastus
lateralis. Specifically, the electrode locations were approximately one-third and two-thirds the
distance from the greater trochanter to the base of the patella (Park et al., 2008; Pietrosimone,
Selkow, Ingersoll, Hart, & Saliba, 2011; Luc et al., 2016). Permanent marker was used to outline
the electrodes to guarantee consistent placement on following testing days. Once the electrode
locations were determined, these areas were shaved with a disposable razor. Oil, debris, and dead
skin cells were removed with hypo-allergenic tape and cleansed with rubbing alcohol. The
electrodes were then placed on the skin and connected to an electrical impedance meter (D175
Electrode Impedance Meter, Digitimer Limited, Hertfordshire, UK) to ensure that impedance
was ≤ 7 kΩ (Park et al., 2008). When impedance was >7 kΩ, the electrodes were removed and
further skin preparation was performed. The electrodes were then connected to a constant-current
stimulator (DS7AH, Digitimer Limited, Hertfordshire, UK). Prior to voluntary contractions, a
series of electrically stimulated isometric contractions of the knee extensors was used to
determine the appropriate amount of electrical stimulation required to maximally activate the
6

quadriceps muscles (Button & Behm, 2008). Subjects were asked to stay as relaxed as possible
during this part of testing. Each stimulation consisted of a paired pulse stimulation, with two 200
ms pulses separated by 10 ms and began at a current of 160 mA. Successive stimulation
intensities were progressively increased by 20 mA and delivered every 20 seconds. Peak
stimulation intensity was determined when peak torque produced via electrical stimulation
reached a plateau or displayed two consecutive decreases. The highest evoked electrical
stimulation value at the beginning of the plateau or before the decline was used for testing (Park
et al., 2008). Electrical stimulation intensity was determined prior to each testing session.
For contractions involving the interpolated twitch technique (ITT), the subjects
performed a six-second maximal voluntary isometric contraction (MVIC) of the knee extensors.
The subjects were provided visual feedback of their torque on a computer monitor, and strong
verbal encouragement was provided. The subjects were specifically instructed to “push hard and
fast.” During all contractions, an investigator carefully observed the torque-time curve. Upon
noticing a clear plateau in torque, the quadriceps femoris muscles were stimulated with a paired
pulse stimulation, and the increase in torque over the voluntary level was measured. The subjects
were instructed to relax upon feeling the stimulation during the MVIC. At ~two and ~four
seconds following the MVIC, the paired pulse stimulation was delivered to the relaxed muscles
to determine peak electrically evoked torque (EET), with the mean of the two values used during
subsequent analyses (Figure 2). Percent voluntary activation was calculated as: 100% x [1(ITT/EET)]. To avoid submaximal effort caused by anticipation of electrical stimulation (Button
& Behm, 2008), during the pretest of Experiment #1 (Figure 1; see text below), the subjects
performed five MVICs separated by two minutes of rest, but were told they may or may not
receive stimulation. The ITT was implemented for three of the five MVICs, and the mean values
7

were used for statistical analyses. The two MVICs without the ITT were discarded. Following
the pretest of Experiment #1, all testing involved on MVIC with ITT, and subjects were told that
electrical stimulation would be administered.

Muscle Fatigue Test
Upon the completion of the post-intervention muscle strength test, the muscle fatigue test
of Experiment #2 began. This test required the subjects to perform 20, six second MVICs. Three
seconds of rest separated each MVIC (i.e., six seconds “on,” three seconds “off”). The subjects
were provided visual feedback on their performance on the computer monitor that was placed in
front of them. Strong verbal encouragement was provided throughout the testing. At the
conclusion of the muscle fatigue test, the subjects performed a final MVIC with a doublet pulse
administered as described previously to examine the decline in voluntary and involuntary
strength.

Surface EMG Signal Recording
Bipolar surface electromyography (EMG) signals were recorded from the vastus lateralis
during the fatigue protocol of Experiment #2 with a Bagnoli 16-channel Desktop system (Delsys,
Inc., Natick, MA, USA). Two sensors were placed over the muscle in close proximity to each
other (one proximal, one distal) to minimize variability (Balshaw 2017). For each dependent
variable, the average value from the two signals has been reported. The signals were detected
with single-differential Bagnoli™ Surface EMG Sensors (Delsys, Inc., Natick, MA, USA). For
each sensor, pairwise subtraction of the two electrodes (interelectrode distance = 10 mm) was
used to derive a single differential EMG channel. The signals were differentially amplified,
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filtered with a bandwidth of 20 Hz to 450 Hz, and sampled at 2,000 Hz. Prior to detecting EMG
signals, the skin over the vastus lateralis and patella was shaved and cleansed with rubbing
alcohol. Oil, debris, and dead skin cells were removed by repeated application and removal of
hypoallergenic tape. The sensors were secured to the vastus lateralis with tape. A reference
electrode was placed over the patella. The EMG sensors were placed over the belly of the vastus
lateralis at 2/3 the distance from the anterior superior iliac spine to the superior border of the
patella, as recommended by the Surface Electromyography for Non-Invasive Muscles project
(Hermens, 2000). Surface EMG signal quality was assessed during the submaximal warm-up
period to ensure low baseline noise and a signal-to-noise ratio ≥ 5.0.

Torque and EMG Signal Processing
The analog signal from the Biodex System 4 isokinetic dynamometer and the surface
EMG signals were acquired with a Shielded Rack-Mount BNC Connector Block (BNC-2090A,
National Instruments, Austin, TX, USA). BNC cables were then used to collect the raw torque
and EMG signals with the Bagnoli 16-channel Desktop system (Delsys, Inc., Natick, MA, USA).
The torque signal was sampled at 2,000 Hz and processed off-line using custom LabVIEW
software (version 8.5, National Instruments, Austin, TX, USA). The raw torque signals were
scaled to units (Nm) and filtered using a zero-phase shift, second-order Butterworth filter with a
50 Hz low-pass cutoff frequency. To analyze peak torque during each MVIC, the highest single
data point was utilized. During each of the 20 MVICs during Experiment #2, vastus lateralis
EMG amplitude was quantified as the root-mean squared (RMS) value (Basmajian and De Luca,
1985) for a two-second interval that encompassed the peak torque value. For the mean frequency
analyses, each selected signal was processed with a Hamming window and the Discrete Fourier
9

Transform was used to generate the power spectrum. The highest peak torque, EMG amplitude,
and EMG mean frequency values from the 20 MVICs were used to normalize all fatigue data
such that all variables have been expressed as a percentage. In addition, neuromuscular
efficiency was calculated by dividing the normalized peak torque generated by the knee
extensors during the MVIC by the normalized vastus lateralis EMG amplitude value (Deschenes
et al., 2009). For each subject and trial, linear regression analyses were used to calculate the
linear slope coefficient (%/MVIC #) for the change in normalized peak torque, vastus lateralis
EMG amplitude and mean frequency, and neuromuscular efficiency.

Subject Assessment Scales
Two scales were used to determine a subject’s subjective energy level and perceived
exertion at various points during the study. First, the subjects were asked to rate their subjective
level of energy with a scale ranging between 0 and 10, with 0 being equivalent to no energy and
10 equivalent to a maximal amount of energy (Appendix F). To determine a subject’s perceived
exertion, a category-ratio scale of 0 to 10 was implemented (Borg, 1998), with 0 representing
“nothing at all” and 10 representing “absolute maximum” (Appendix G). The Subjective
Assessment of Energy Scale was shown to the subjects before and 15 minutes after the
administration of an intervention, and both scales were shown after the muscle fatigue test.

Administration of Intervention
On three separate days, subjects consumed a placebo supplement, an open-label placebo
supplement, or engaged in a control condition. All supplements contained flour, with the placebo
and open-label placebo capsules being red and blue, respectively. Red capsules have been
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associated with stimulant-like effects, whereas blue is related to a calming effect (de Craen,
1996). Both supplementation days required the subjects to consume two capsules, and they were
provided 591 ml of water that they could consume ad libitum.
After completing the percent voluntary activation testing, an immediate 15 minute rest
period began. At the beginning of the rest period, an oral script was delivered depending on the
intervention of that day. For the control trial, subjects were told there would be no administration
of an intervention and to sit quietly for the duration of the 15 minutes (Appendix H). For the
open-label placebo supplement trial, subjects were told that they would be consuming capsules
that had no active ingredients and should not feel any effects (Appendix I). For the placebo
supplement trial, subjects were told they were consuming a dietary supplement that research had
shown to effectively improve strength, delay fatigue, and make them “feel more energetic”
(Appendix J). After the administration of an intervention, the subjects remained seated on the
dynamometer until the conclusion of the 15 minute rest period. The laboratory remained quiet
during the rest period. The primary investigator involved in data collection and analysis
remained blinded to the intervention each subject received, and left the laboratory for this portion
of testing.

Statistical Analyses
Mean differences in MVIC peak torque, percent voluntary activation, and subjective
energy levels were evaluated with two-way (intervention [placebo, open-label placebo, control]
× time [pre-intervention, post-intervention]) repeated measures analyses of variance (ANOVAs).
Differences in the linear slope coefficients and rating of perceived exertion were examined with
one-way (placebo, open-label placebo, control) repeated measures ANOVAs. For the fatigue
11

data, changes in each of the dependent variables across the MVICs were evaluated with two-way
(intervention [placebo, open-label placebo, control] × MVIC # [#1, #2, #3, #4, #5, etc.]) repeated
measures ANOVAs. When appropriate, follow-up procedures included repeated measures
ANOVAs, paired samples t-tests, and Bonferroni post hoc comparisons. The partial eta squared
(η2) statistic was used to evaluate the effect size for each ANOVA. Stevens (2007) characterized
η2 = .01 as corresponding to a small effect size, η2 = .06 to a medium effect size, and η2 = .14 to
a large effect size. An alpha level of 0.05 was used to determine statistical significance for all
procedures. SPSS software (version 23.0, IBM Corporation, Armonk, NY, USA) was used for all
statistical analyses.
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Figure 1. An overview of the study procedures. Experiment #1 was designed to examine the acute effects of placebo and openlabel placebo supplementation on muscle strength and percent voluntary activation, whereas Experiment #2 assessed fatigue
resistance.
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Figure 2. Percent voluntary activation determined through muscle strength testing with electrical
stimulation.
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CHAPTER THREE: RESULTS
Experiment #1
Percent Voluntary Activation
The mean ± SD percent voluntary activation values for the pretest and posttest,
respectively, were as follows: (1) placebo = 94.4 ± 8.3 and 94.6 ± 7.8%, (2) OLP = 95.6 ± 6.3
and 92.7 ± 8.8%, (3) control = 93.6 ± 8.1 and 91.6 ± 9.3%. The results from the two-way
repeated measures ANOVA indicated that there was no time × intervention interaction (F = .557,
p = .567, η2 = .027) and no main effects for time (F = 3.071, p = .095, η2 = .133) or intervention
(F = 1.061, p = .351, η2 = .050).
As part of a secondary aim, an analysis of subjects that consistently demonstrated
voluntary activation less than 100% was performed (n= 7). The mean ± SD percent voluntary
activation values for the pretest and posttest, respectively, were as follows: (1) placebo = 87.9 ±
11.0 and 91.6 ± 8.7%, (2) OLP = 89.2 ± 5.6 and 86.9 ± 8.9%, (3) control = 83.7 ± 5.2 and 87.2 ±
9.6%. The results from the two-way repeated measures ANOVA indicated that there was no time
× intervention interaction (F = .615, p = .525, η2 = .093) and no main effects for time (F = 1.012,
p = .379, η2 = .144) or intervention (F = 5.175, p = .063, η2 = .463).
Peak Torque
The mean ± SD peak torque values for the pretest and posttest, respectively, were as
follows: (1) placebo = 170.4 ± 55.1 and 174.6 ± 54.0 Nm, (2) OLP = 172.2 ± 56.6 and 172.1 ±
61.9 Nm, (3) control = 164.1 ± 59.8 and 166.0 ± 60.9 Nm. The results from the two-way
repeated measures ANOVA indicated that there was no time × intervention interaction (F = .550,
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p = .566, η2 = .027) and no main effects for time (F = 3.296, p = .084, η2 = .141) or intervention
(F = 1.477, p = .242, η2 = .069).
As part of a secondary aim, an analysis of subjects that consistently demonstrated
voluntary activation less than 100% was performed (n= 7). The mean ± SD percent voluntary
activation values for the pretest and posttest, respectively, were as follows: (1) placebo = 166.8 ±
38.2 and 170.8 ± 35.4%, (2) OLP = 169.8 ± 40.5 and 165.0 ± 47.7%, (3) control = 157.5 ± 42.9
and 162.5 ± 42.5%. The results from the two-way repeated measures ANOVA indicated that
there was no time × intervention interaction (F = 1.505, p = .264, η2 = .201) and no main effects
for time (F = .386, p = .557, η2 = .060) or intervention (F = .705, p = .513, η2 = .105).
Subjective Assessment of Energy
The mean ± SD reported level of energy for the pretest and posttest, respectively, were as
follows: (1) placebo = 5.5 ± 2.0 and 6.1 ± 2.1, (2) OLP = 5.6 ± 2.3 and 5.8 ± 2.3, (3) control =
5.2 ± 2.0 and 5.5 ± 2.0. The results from the two-way repeated measures ANOVA indicated that
there was no time × intervention interaction (F = 1.516, p = .234, η2 = .070) and no main effect
for intervention (F = .646, p = .529, η2 = .031). There was, however, a main effect for time (F =
6.915, p = .016, η2 = .257), and the Bonferroni pairwise comparison indicated that the reported
level of energy at the posttest was significantly greater than that during the pretest.
As part of a secondary aim, an analysis of subjects that consistently demonstrated
voluntary activation less than 100% was performed (n= 7). The mean ± SD percent voluntary
activation values for the pretest and posttest, respectively, were as follows: (1) placebo = 4.9 ±
2.1 and 5.4 ± 2.1%, (2) OLP = 4.9 ± 2.1 and 5.1 ± 2.1%, (3) control = 4.1 ± 2.0 and 4.5 ± 1.4%.
The results from the two-way repeated measures ANOVA indicated that there was no time ×
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intervention interaction (F = .227, p = .776, η2 = .036) and no main effects for time (F = 1.740, p
= .235, η2 = .225) or intervention (F = .735, p = .471, η2 = .109).

Experiment #2
Percent Voluntary Activation Following Fatigue
The mean ± SD percent voluntary activation values following the fatiguing protocol for
the pretest and posttest, respectively, were as follows: (1) placebo = 94.6 ± 7.8 and 88.1 ± 17.7%,
(2) OLP = 92.7 ± 8.8 and 87.7 ± 13.7%, (3) control = 91.6 ± 9.3 and 87.3 ± 16.6%. The results
from the two-way repeated measures ANOVA indicated that there was no time × intervention
interaction (F = .180, p = .784, η2 = .009) and no main effects for time (F = 2.655, p = .199, η2 =
.117) or intervention (F = 0.288, p = .749, η2 = .014).
Peak Torque Following Fatigue
The mean ± SD reported peak torque values following the fatiguing protocol for the
pretest and posttest, respectively, were as follows: (1) placebo = 174.6 ± 54.0 and 135.7 ± 39.0,
(2) OLP = 172.1 ± 61.9 and 137.7 ± 41.4, (3) control = 166.1 ± 60.7 and 130.5 ± 37.7. The
results from the two-way repeated measures ANOVA indicated that there was no time ×
intervention interaction (F = .387, p = .643, η2 = .019) and no main effect for intervention (F =
2.006, p = .153, η2 = .091). There was, however, a main effect for time (F = 43.824, p = .001, η2
= .687), and the Bonferroni pairwise comparison indicated that the peak torque values at the
posttest was significantly less than those during the pretest (marginal means = 170.9 and 134.7,
respectively).
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Slope for the Decline in Normalized Peak Torque
The mean ± SD slope for the decline in normalized peak torque values were as follows:
(1) placebo = -1.682 ± 1.061, (2) OLP = -1.907 ± .945, (3) control = -1.821 ± 0.863. The
repeated measures ANOVA was not statistically significant (F = 1.088, p = .346, η2 = .052).
Slope for the Decline in Normalized EMG Mean Frequency
The mean ± SD slope for the decline in normalized EMG mean frequency values were as
follows: (1) placebo = -.955 ± .933, (2) OLP = -1.041 ± .552, (3) control = -1.004 ± .674. The
repeated measures ANOVA was not statistically significant (F = .154, p = .783, η2 = .008).
Slope for the Decline in Normalized Neuromuscular Efficiency
The mean ± SD slope for the decline in normalized neuromuscular efficiency values were
as follows: (1) placebo = -.020 ± .032, (2) OLP = -.029 ± .015, (3) control = -.025 ± .013. The
repeated measures ANOVA was not statistically significant (F = 1.381, p = .260, η2 = .068).
Decline in Absolute Peak Torque
The results from the two-way repeated measures ANOVA indicated that there was no
MVIC # × intervention interaction (F = .887, p = .506, η2 = .042) and no main effect for
intervention (F = .988, p = .378, η2 = .047). There was, however, a main effect for MVIC # (F =
41.551, p = .001, η2 = .675), and the Bonferroni pairwise comparisons indicated that the decline
in peak torque from MVIC #1 became statistically significant at MVIC #7. From MVIC #1 to
MVIC #20, the mean percent decline in peak torque was 34.4%.
Decline in Normalized Peak Torque
The results from the two-way repeated measures ANOVA indicated that there was no
MVIC # × intervention interaction (F = .945, p = .480, η2 = .045) and no main effect for
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intervention (F = 1.650, p = .206, η2 = .076). There was, however, a main effect for MVIC # (F =
65.010, p = .001, η2 = .765), and the Bonferroni pairwise comparisons indicated that the decline
in peak torque from MVIC #1 became statistically significant at MVIC #7. From MVIC #1 to
MVIC #20, the mean percent decline in peak torque was 30.9%.
Decline in Normalized EMG Amplitude
The results from the two-way repeated measures ANOVA indicated that there was no
MVC # × intervention interaction (F = .922, p = .506, η2 = .046) and no main effects for MVC #
(F = 1.244, p = .302, η2 = .061) or intervention (F = 1.867, p = .171, η2 = .089).
Decline in Normalized EMG Mean Frequency
The results from the two-way repeated measures ANOVA indicated that there was no
MVIC # × intervention interaction (F = .888, p = .548, η2 = .045) and no main effect for
intervention (F = 3.285, p = .051, η2 = .147). There was, however, a main effect for MVIC # (F =
24.656, p = .001, η2 = .565), and the Bonferroni pairwise comparisons indicated that the decline
in EMG mean frequency from MVIC #1 became statistically significant at MVIC #6. From
MVIC #1 to MVIC #20, the mean percent decline in EMG mean frequency was 21.1%.
Decline in Neuromuscular Efficiency
The results from the two-way repeated measures ANOVA indicated that there was no
MVIC # × intervention interaction (F = .1.303, p = .272, η2 = .064) and no main effect for
intervention (F = 2.653, p = .099, η2 = .123). There was, however, a main effect for MVIC # (F =
26.805, p = .001, η2 = .585), and the Bonferroni pairwise comparisons indicated that the decline
in neuromuscular efficiency from MVIC #1 became statistically significant at MVIC #5. From
MVIC #1 to MVIC #20, the mean percent decline in neuromuscular efficiency was 38.4%.
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Subjective Assessment of Energy
The mean ± SD reported level of energy for the pretest and posttest, respectively, were as
follows: (1) placebo = 6.1 ± 2.1 and 4.5 ± 2.3, (2) OLP = 5.8 ± 2.3 and 3.8 ± 2.2, (3) control =
5.5 ± 2.0 and 3.7 ± 2.2. The results from the two-way repeated measures ANOVA indicated that
there was no time × intervention interaction (F = .488, p = .615, η2 = .022) and no main effect for
intervention (F = 2.562, p = .090, η2 = .144). There was, however, a main effect for time (F =
9.271, p = .006, η2 = .317), and the Bonferroni pairwise comparison indicated that the reported
level of energy at the pretest was significantly greater than that during the posttest.
Rating of Perceived Exertion
The mean ± SD rating of perceived exertion values after the fatiguing protocol were as
follows: (1) placebo = 6.3 ± 2.2, (2) OLP = 6.5 ± 2.3, (3) control = 6.5 ± 2.0. The repeated
measures ANOVA was not statistically significant (F = .208, p = .788, η2 = .010).
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Figure 3. Percent voluntary activation for pretest and posttest.
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Figure 4. Percent voluntary activation for pretest and posttest for subjects that demonstrated less
than 100% voluntary activation.
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Figure 5. Peak torque for pretest and posttest.
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Figure 6. Peak torque for pretest and posttest for subjects that demonstrated less than 100%
voluntary activation.
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Figure 7. Subjective assessment of energy for pretest and posttest
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Figure 8. Subjective assessment of energy for pretest and posttest for subjects that demonstrated
less than 100% voluntary activation.
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Figure 9. Percent voluntary activation following fatigue.
24

Control

Pre

Post

Peak Torque Following Fatigue (%)

200.0

150.0

100.0
174.6

172.1

166.1
137.7

135.7

130.5

50.0

0.0
Placebo

OLP

Control

OLP

Control

Figure 10. Peak torque following fatigue.
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Figure 11. Slope for the decline in normalized peak torque.
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Figure 12. Slope for the decline in normalized EMG mean frequency
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Figure 13. Slope for the decline in normalized neuromuscular efficiency.
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Figure 14. Decline in absolute peak torque.
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Figure 15. Decline in normalized peak torque.
27

Placebo

OLP

Control

90.0

EMG Amplitude (%)

80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0

MVIC #

Figure 16. Decline in normalized EMG amplitude.
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Figure 17. Decline in normalized EMG mean frequency.
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Figure 18. Decline in neuromuscular efficiency.
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Figure 19. Subjective assessment of energy pre- and post- fatigue.
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Figure 20. Rating of Perceived Exertion.
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CHAPTER FOUR: DISCUSSION
The results of this study indicated that there was no statistical significance between the
time and intervention interaction for both experiment #1 and #2. Also, there was no statistical
significance between the MVIC # and intervention interaction for experiment #2. There was no
main effect for intervention for any components in experiment #1 and #2. However, there was a
main effect for time and MVIC # for certain aspects of the study.
In experiment #1, when examining the subjective assessment of energy for pre- and postintervention there was a main effect for time. This indicates that with all the interventions there
was an increase in energy from pretest to posttest. In experiment #2, there was a main effect for
time when examining peak torque following the fatiguing protocol. This main effect shows that
with all intervention phases there was a decrease in peak torque values from pretest to posttest.
The decrease in peak torque over the protocol indicates that fatigue occurred during all
interventions. Also in experiment #2, there was a main effect for time for the subjective
assessment of energy. The results display that the energy levels were greater during pretest than
at posttest meaning energy level decreased for all interventions.
In experiment #2, main effect for MVIC # was seen in absolute peak torque, normalized
peak torque, normalized EMG mean frequency, and neuromuscular efficiency. For all of these
components, having a main effect in MVIC # means a decrease occurred from MVIC #1 to
MVIC #20, which indicates that fatigue occurred during the protocol. For absolute peak torque,
the decline in torque became significant at MVIC # 7 with a mean percent decrease of 34.4% in
peak torque values over the 20 repetitions. Normalized peak torque experienced a 30.9%
decrease and became significant at MVIC #7. The mean decline in EMG mean frequency
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became significant at MVIC #6 and was 21.2%. The decline in neuromuscular efficiency was
38.4% and was significant at MVIC #5.
This study found that no intervention played a significant role in producing a change in
muscle strength, percent voluntary activation, or muscle fatigue. Majority of recent OLP clinical
trials found positive results with the exception of the major depressive disorder study. Like this
study, the major depressive disorder research found that the introduction of an OLP treatment did
not help improve symptoms in comparison to no treatment. There are several potential reasons
that there were no significant results found in this study.
There is a possibility that the subject population and the type of disorder or illness play a
role in finding significant results. The clinical trials with positive results have patient populations
that had preexisting illnesses or disorders and are seeking of relief. In this study, we asked for
healthy, untrained individuals which could have been a potential limitation to our study due to
the absence of an illness/disorder. The psychological pressure of wanting relief from an illness
could alter the outcome of treatment. Another limitation could have been training status. The
requirement of this study asked for sedentary, healthy adults. It was apparent that some subjects
were trained and had a desire to participate in research regardless of requirements. Also, having a
monetary reward for completion of the study could have introduced bias and changed the
subject’s performance during the experiment.
Increasing population size could potentially increase the likelihood of an intervention
playing a role on the protocol. Increasing the number of days a subject ingested each intervention
could have altered the outcomes. In the other clinical trials, more than one day was allotted to
take the OLP treatment, which could have caused an expectation or conditioning effect. Most
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researchers attribute these brain mechanisms to be the reason for the effectiveness for OLP
treatment even though they have not been proven to cause an effect.
The role of placebo and open-label placebo supplementation in delaying neuromuscular
fatigue is worthy of scientific inquiry. Even though the results of this study were limited,
potentially changing the subject population, changing the verbal communication during the
administration of placebos, or providing source information to the subjects prior to participation
could be lead to different findings. By using the OLP treatment, subjects or patients are able to
keep their autonomy which prevents the unethical issues that arise from using placebo
treatments. Evidently, the clinical trials have shown profound results with using OLP treatment
and should be continued.
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